A Pilot Study Investigating the Effect of Caralluma Fimbriata Extract on the Risk Factors of Metabolic Syndrome in Overweight and Obese Subjects: A Randomised Controlled Clinical Trial
This 12-week randomized, double-blind, placebo-controlled clinical trial assessed the effects of Caralluma fimbriata extract on metabolic syndrome risk factors in 33 overweight and obese adults. Participants received 1 g/day of Caralluma fimbriata extract or placebo, alongside controlled dietary intake and physical activity. The Caralluma group experienced a greater reduction in